These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22234690)

  • 1. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
    Goodyear OC; Dennis M; Jilani NY; Loke J; Siddique S; Ryan G; Nunnick J; Khanum R; Raghavan M; Cook M; Snowden JA; Griffiths M; Russell N; Yin J; Crawley C; Cook G; Vyas P; Moss P; Malladi R; Craddock CF
    Blood; 2012 Apr; 119(14):3361-9. PubMed ID: 22234690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
    Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
    Craddock C; Slade D; De Santo C; Wheat R; Ferguson P; Hodgkinson A; Brock K; Cavenagh J; Ingram W; Dennis M; Malladi R; Siddique S; Mussai F; Yap C
    J Clin Oncol; 2019 Mar; 37(7):580-588. PubMed ID: 30653424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant.
    Yamamoto W; Tachibana T; Ogusa E; Matsumoto K; Maruta A; Ishigatsubo Y; Kanamori H
    Leuk Lymphoma; 2013 Sep; 54(9):2079-80. PubMed ID: 23297798
    [No Abstract]   [Full Text] [Related]  

  • 5. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
    Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
    Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
    Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
    Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
    Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Wang J; Zhou J; Zheng HF; Fu ZZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1448-52. PubMed ID: 25338605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analyses of leukemia-associated antigen-specific CD8
    Rücker-Braun E; Link CS; Schmiedgen M; Tunger A; Vizjak P; Teipel R; Wehner R; Kühn D; Fuchs YF; Oelschlägel U; Germeroth L; Schmitz M; Bornhäuser M; Schetelig J; Heidenreich F
    Exp Hematol; 2016 Nov; 44(11):1024-1033.e1. PubMed ID: 27473564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
    Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
    Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
    Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
    Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
    Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
    Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
    Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.